Somaxon Raises $5M

6/13/11

San Diego’s Somaxon Pharmaceuticals (NASDAQ: SOMX), said today it completed a private placement of nearly 2.2 million shares of its common stock to Paladin Labs, raising a total of $5 million. The company said the deal was part of its collaboration with Paladin, which has exclusive rights to commercialize Somaxon’s doxepin (Silenor) in Canada, South America, and Africa.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.